"We have entered a new phase of the pandemic where solidarity is needed like never before”, says @DrTedros at @WHO presser on #covid19.
"We are in a race to save lives right now."
@DrTedros@WHO “Case loads are so high in several countries that hospitals and intensive care units are filling up to dangerous levels”, says @drtedros. People mixed more indoors during holidays, he says. “New variants which appear to be more transmissible are exacerbating the situation."
@DrTedros@WHO "We are in a race to prevent infections, bring cases down, protect health systems and save lives, while rolling out highly effective and safe vaccines to high risk populations”, says @DrTedros. "his is not easy. These are the hard miles, we must tread together."
@DrTedros@WHO “If we act together, we can win both races and get ahead of the virus while also limiting the opportunity for the virus to mutate further and threaten the health tools we currently have”, says @DrTedros.
@DrTedros@WHO “We owe it morally to health workers everywhere, who have been fighting this pandemic around the clock for the best part of a year, to vaccinate them all as soon as possible”, says @drtedros. "People must come first over short-term profits."
@DrTedros@WHO “Over the past 24 hours, members of the international scientific team on #COVID19 virus origins began traveling from their home countries to China”, says @drtedros. "Today, we learned that Chinese officials have not yet finalized the necessary permissions for the team's arrival"
@DrTedros@WHO "I'm very disappointed with this news, given that two members had already begun their journeys and others were not able to travel at the last minute”, says @drtedros. "I have once again made it clear that the mission is a priority for @WHO, and the international team."
@DrTedros@WHO “I have been assured that China is speeding up the internal procedures for the earliest possible deployment”, says @drtedros. "We are eager to get the mission underway as soon as possible.”
(What a slap in the face to @WHO after months of negotiating this.)
@DrTedros@WHO Alejandro Cravioto, who chairs Strategic Advisory Group of Experts on Immunization (SAGE) gives an overview of what the group has recommended on Pfizer #covid19 vaccine: “SAGE recommends the administration of two doses of this vaccine within 21 to 28 days."
@DrTedros@WHO There is little data on safety and efficacy after one dose beyond the 3-4 weeks, says Cravioto. But SAGE still made a provision for countries in exceptional circumstances "to delay the administration of the second dose for a few weeks”.
@DrTedros@WHO On anaphylactic reactions: "SAGE recommended that the vaccine should be administered only in settings where anaphylaxis can be treated”, says Cravioto.
@DrTedros@WHO "In light of the data limitations, SAGE was not able to provide a recommendation for the use of the vaccine in pregnancy until more safety data are available”, says Cravioto, though exceptions for instance for pregnant health workers at high risk of exposure.
@DrTedros@WHO “SAGE recommends that COVID vaccination be offered regardless of a person's history of asymptomatic or symptomatic SARS infection”, says Cravioto.
@DrTedros@WHO Since symptomatic reinfection within 6 month is rare, recently infected people may delay vaccination for a while. "This would encourage the use of the vaccines for other people who have not been exposed to the virus and thus have a much larger portion of the population protected"
@DrTedros@WHO "It's really important the national governments who are issuing vaccines and distributing vaccines to sub-national level are also aware of the investments that are needed to shore up the capacity of the system to deliver those vaccines at the local level”, says @DrMikeRyan.
@DrTedros@WHO@DrMikeRyan "You can't file and forget, you can't dispatch and forget. You have to drive and follow each vaccine right into the arm of the person who has to get it”, says @DrMikeRyan. “Quite frankly, many countries may have been overconfident in their ability to do this."
@DrTedros@WHO@DrMikeRyan "We hope that this is just a logistic and bureaucratic issue that can be resolved very quickly”, says @DrMikeRyan on China snafu. "This is frustrating and as the Director General has said this is disappointing.”
@DrTedros@WHO@DrMikeRyan (Missed part of the presser for an interview. Will check and add anything important I missed to this thread latter.)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I’ve said before that I’m watching Denmark closely for clues on #B117, so a short update.
The Statens Serum Institut @SSI_dk has an interesting note here on the spread of B.1.1.7 (I’m using google translate): ssi.dk/aktuelt/nyhede…
@SSI_dk While cases in Denmark are declining and percentage of #B117 is still low, experts there expect that percentage to keep growing and estimate that the new variant could make up half of all infections in Denmark in 40-50 days.
@SSI_dk If that is true and #B117 takes over Danish experts expect cases in the country to rise again. By how much depends on how low the reproduction number R is.
The scientists estimate that reducing R to 0.7 (for the old variants) would keep the new variant from spreading too.
I’ve written a lot in the last two weeks about #B117 and the uncertainty surrounding its exact effects.
So let me talk about something that we can be pretty certain about: what we should be doing.
New story is here: sciencemag.org/news/2021/01/v…
Quick thread to come.
First: How good is the evidence that #B117 is more transmissible? It’s still far from a slam dunk. But as @AdamJKucharski told me: “We're relying on multiple streams of imperfect evidence, but pretty much all that evidence is pointing in the same direction now.”
At this point we probably have to look to countries other than the UK for confirmation that #B117 is more transmissible.
“The dynamics and the spread of this strain internationally is probably going to be the strongest evidence we will have”, @EvolveDotZoo told me.
We’re in a new year and we have also entered a new phase of this pandemic. So I thought I’d start off the new year with a quick catch-up thread on the UK variant B.1.1.7 and where we are at in this pandemic.
The variant caught scientists' attention in early December based on a surge in cases around Kent and sequencing data showing it carried a host of mutations. (I wrote about this and how a quirk in the PCR is helping track it here: sciencemag.org/news/2020/12/m…).
CAVEAT: The pace at which we have learnt about this new variant is astonishing. But it’s important to realize that a lot of crucial lab experiments take longer. Most data now is looking at noisy epidemiological data and making inferences based on that.
"Although there is no information that infections with these strains are more severe, due to increased transmissibility the impact of #COVID19 disease in terms of hospitalisations and deaths is assessed as high."
@ECDC_EU "The probability of increased circulation of any SARS-CoV-2 strains and this placing greater pressure on health systems in the coming weeks is considered to be high due to the festive season and, higher still, in countries where the new variants are established."
@ECDC_EU "The UK has demonstrated that their sequencing programme is able to detect emerging variants. Ideally, Member States should aim for a similar timeliness and fraction of samples sequenced, although this will depend on the availability of resources."
Finally read the new update on UK variant B.1.1.7, posted yesterday, which includes a study suggesting the variant is no more (or less) severe than prior virus variants.
Just a very brief thread (or read the entire document here: assets.publishing.service.gov.uk/government/upl…)
Researchers took 1769 cases of people infected with the new variant and then looked for 1769 cases of people with “normal” virus to compare them to. They chose these so that median age and proporion of females was the same. That’s why it’s called a “matched cohort study”
They then compared hospitalizations for the two groups:
Overall 42 people were hopsitalized,
16 with the variant
26 with wild-type
The difference between the two was not significant.
"This is a moment for all of us to reflect on the toll the pandemic has taken, the progress we have made, the lessons we have learned and what we need to do in the year ahead to end this pandemic”, says @DrTedros in last @WHO#covid19 presser of the year.
@DrTedros@WHO "Science is at the core of everything we do and it has advanced at a blistering speed this year”, says @drtedros.
@DrTedros@WHO "There will be setbacks and new challenges in the year ahead”, says @DrTedros. "For example, new variants of #COVID19 and helping people who are tired of the pandemic continue to combat it."